INHALATION-TYPE PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF KIDNEY DISEASE AND PREPARATION METHOD THEREOF

• US 20150297513A1
• Filed: 03/23/2015
• Published: 10/22/2015
• Est. Priority Date: 04/18/2014
• Status: Abandoned Application

• Current Assignee: Hsin-Yung Lin
• Original Assignee: Hsin-Yung Lin
• Inventors: Lin, Hsin-Yung
• Application Number:
  US14/665,989
• Publication Number:
  US 20150297513A1
• Time in Patent Office: Days
• US Class Current: 1/1
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 31/573 substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• CPC Class Codes: A61K 38/1816 Erythropoietin [EPO]
• CPC Class Codes: A61K 9/008 comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
• CPC Class Codes: A61P 13/12 of the kidneys

Abstract

The present invention provides an inhalation-type pharmaceutical composition for kidney disease and preparation method thereof, comprising a first gas and an atomized medicine. The first gas comprises hydrogen. The gas volume concentration of hydrogen in the inhalation-type pharmaceutical composition is between 2 to 96%. The atomized medicine is selected from a group comprising corticosteroid, angiotensin converting enzyme inhibitor, angiotensin II receptor blocker, diuretics, erythropoietin, phosphate binding agent, and any combination thereof. The inhalation-type pharmaceutical composition of the present invention can remove harmful radicals in the body of the patient through the use of hydrogen while also increases the absorption effect of the medicine for the patient by using an atomized medicine. At the same time, because the use of the small amount of the vaporized pharmaceutical liquid can indirectly reduce the side effects on the user.

Claims

1. An inhalation-type pharmaceutical composition for the treatment of kidney disease, comprising a first gas and an atomized medicine, wherein the first gas comprises hydrogen, the gas volume concentration of hydrogen in the inhalation-type pharmaceutical composition is between 2 to 96%, the atomized medicine is selected from a group comprising corticosteroid, angiotensin converting enzyme inhibitor, angiotensin II receptor blocker, diuretics, erythropoietin, phosphate binding agent, and any combination thereof.

2. The inhalation-type pharmaceutical composition for the treatment of kidney disease of claim 1, wherein the first gas further comprises oxygen.

3. The inhalation-type pharmaceutical composition for the treatment of kidney disease of claim 2, wherein the first gas is a gas mixture of hydrogen and oxygen generated from electrolyzing water, where the volume ratio of hydrogen to oxygen is about 2:

1.

4. The inhalation-type pharmaceutical composition for the treatment of kidney disease of claim 2, further comprising a second gas for reducing the gas volume concentration of hydrogen in the inhalation-type pharmaceutical composition, wherein the second gas is a gas selected from a group comprising air, water vapor, inert gas, oxygen or any combination thereof.

5. The inhalation-type pharmaceutical composition for the treatment of kidney disease of claim 1, wherein the gas volume concentration of hydrogen in the inhalation-type pharmaceutical composition is between 2 to 66.66%.

6. The inhalation-type pharmaceutical composition for the treatment of kidney disease of claim 1, wherein the gas volume concentration of hydrogen in the inhalation-type pharmaceutical composition is between 4.7 to 66.66%.

7. The inhalation-type pharmaceutical composition for the treatment of kidney disease of claim 1, wherein the gas volume concentration of hydrogen in the inhalation-type pharmaceutical composition is between 60 to 66.66%.

8. The inhalation-type pharmaceutical composition for the treatment of kidney disease of claim 1, wherein the gas volume concentration of hydrogen in the inhalation-type pharmaceutical composition is larger than 66.66%.

9. The inhalation-type pharmaceutical composition for the treatment of kidney disease of claim 1, wherein the atomized medicine is generated by atomizing or vaporizing a medicinal liquid.

10. The inhalation-type pharmaceutical composition for the treatment of kidney disease of claim 9, wherein the medicinal liquid is selected from a group comprising corticosteroid, angiotensin converting enzyme inhibitor, angiotensin II receptor blocker, diuretics, erythropoietin, phosphate binding agent, and any combination thereof.

11. A preparation method for an inhalation-type pharmaceutical composition for the treatment of kidney disease, comprising the following steps:

(S1) preparing a first gas, wherein the first gas comprising hydrogen;

(S2) atomizing a medicinal liquid in order to generate an atomized medicine, wherein the atomized medicine is selected from a group comprising corticosteroid, angiotensin converting enzyme inhibitor, angiotensin II receptor blocker, diuretics, erythropoietin, phosphate binding agent, and any combination thereof; and

(S3) mixing the first gas and the atomized medicine in order to generate the inhalation-type pharmaceutical composition, wherein the gas volume concentration of hydrogen in the inhalation-type pharmaceutical composition is between 2 to 96%.

12. The preparation method for the inhalation-type pharmaceutical composition for the treatment of kidney disease of claim 11, further comprising the following step after step (S2):

(S23) preparing a second gas.

13. The preparation method for the inhalation-type pharmaceutical composition for the treatment of kidney disease of claim 12, wherein in step (S3), the inhalation-type pharmaceutical composition is generated from mixing the first gas, the second gas, and the atomized medicine.

14. The preparation method for the inhalation-type pharmaceutical composition for the treatment of kidney disease of claim 12, wherein the second gas is used for reducing the gas volume concentration of hydrogen in the inhalation-type pharmaceutical composition.

15. The preparation method for the inhalation-type pharmaceutical composition for the treatment of kidney disease of claim 12, wherein the second gas is a gas selected from a group comprising air, water vapor, inert gas, oxygen or any combination thereof.

16. The preparation method for the inhalation-type pharmaceutical composition for the treatment of kidney disease of claim 11, wherein in step (S1), the first gas is generated by electrolyzing water, the first gas comprises a gas mixture of hydrogen and oxygen, where the volume ratio of hydrogen to oxygen is 2:

1.

17. The preparation method for the inhalation-type pharmaceutical composition for the treatment of kidney disease of claim 11, wherein the gas volume concentration of hydrogen in the inhalation-type pharmaceutical composition is between 2 to 66.66%.

18. The preparation method for the inhalation-type pharmaceutical composition for the treatment of kidney disease of claim 11, wherein the gas volume concentration of hydrogen in the inhalation-type pharmaceutical composition is between 4.7 to 66.66%.

19. The preparation method for the inhalation-type pharmaceutical composition for the treatment of kidney disease of claim 11, wherein the gas volume concentration of hydrogen in the inhalation-type pharmaceutical composition is between 60 to 66.66%.

20. The preparation method for the inhalation-type pharmaceutical composition for the treatment of kidney disease of claim 11, wherein the gas volume concentration of hydrogen in the inhalation-type pharmaceutical composition is larger than 66.66%.